The BioPharmaDispatch analysis of the recently released annual PBS Expenditure and Prescriptions report has confirmed the challenge of assessing the scheme based on spending growth but confirms how it has effectively transformed into two programs.
Latest Video
New Stories
-
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News -
Time to make this 'targeted' consultation a little less targeted
May 5, 2026 - - Latest News -
Australia approves first in class therapy for chronic graft versus host disease
May 5, 2026 - - Latest News -
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 - - Latest News -
Medicines Australia calls for transparency, highlighting the risk of bias
May 5, 2026 - - Latest News
